Common misconceptions and why pharmaceutical market is so different. List price, co pays and deductibles, oh my. Bio similars v small molecule, how the evolution here promises great things. Competition is real and generates real savings, and deflation. Opportunity for savings was real, IRA causing disruption to that. Cell and gene therapies are just the latest revolution for patients therapies: branded drugs, generic medicines, small molecule, bio similar. Who pays for these high cost, high reward solutions. How does performance play a role?